What Does Substance P Do in the Body?

Substance P is a small signaling molecule, just eleven amino acids long, that acts as a messenger throughout the nervous system and beyond. Its most recognized job is relaying pain signals from the body to the spinal cord and brain, but that role barely scratches the surface. Substance P influences inflammation, nausea, mood, gut motility, wound healing, heart function, and even tumor behavior. Few molecules in the body wear as many hats, and understanding what substance P actually does helps explain why it keeps showing up in research on conditions as different as depression and brain trauma.

Carrying the Pain Signal

Substance P earned its name (the “P” originally stood for “powder” or “preparation,” depending on who tells the story) partly because of its deep connection to pain. It is produced inside a specific subset of small-diameter sensory nerve fibers, the ones responsible for detecting tissue damage and sending that information toward the spinal cord.¹ These fibers, sometimes called C-fibers and Aδ-fibers, are the slow-burning pain channels, the ones involved in aching, burning, or throbbing sensations rather than the sharp, immediate “ouch” of touching something hot.

When you stub your toe or twist an ankle, those nerve fibers release substance P at their terminals in the spinal cord. There it activates the neurokinin-1 receptor (NK1R) on the next set of neurons in the chain, amplifying and forwarding the pain message upward to the brain.² Substance P is also produced in brain regions involved in processing pain, so it participates both at the entry point in the spinal cord and in the higher-level circuits that determine how intensely you experience that pain.³

What makes substance P particularly relevant to chronic pain is that its release does not just track with the severity of an injury. Over time, persistent substance P signaling can sensitize the spinal cord neurons it acts on, lowering the threshold for future pain signals. Elevated levels of substance P have been linked to heightened pain sensitivity and to psychiatric conditions that often accompany chronic pain, including depression, anxiety disorders, and PTSD.⁴

Triggering Neurogenic Inflammation

Pain signaling is only part of the picture. Substance P also drives a process called neurogenic inflammation, where sensory nerves themselves cause swelling, redness, and warmth in surrounding tissue. When substance P is released at the peripheral end of those sensory fibers (out in the skin, joints, or organs rather than at their spinal cord end), it causes nearby blood vessels to become leaky, allowing fluid and immune cells to flood into the tissue.

This vascular leakiness occurs specifically in postcapillary venules, the tiny vessels where immune cells normally exit the bloodstream. Research using electron microscopy confirmed that substance P-driven permeability was restricted to these venules and, interestingly, could occur even in animals almost completely lacking mast cells. That finding challenged an earlier assumption that mast cells were the essential middlemen in neurogenic inflammation and showed that substance P can act directly on the vessel walls.⁵

This direct vascular effect helps explain the “triple response” you see when skin is scratched: the initial red line, the surrounding flare, and the raised wheal. Substance P released from local nerve endings contributes to all three. The same mechanism operates in joints, the gut lining, and the airways, making neurogenic inflammation a common thread linking substance P to arthritis, inflammatory bowel disease, and asthma.

Nausea and Vomiting

If you or someone you know has undergone chemotherapy, there is a good chance you have encountered substance P’s influence without knowing it. Chemotherapy drugs trigger nausea in two waves. The early wave, within the first day, is driven mostly by serotonin. The later, delayed phase involves substance P release in the gut, which then activates NK1 receptors in brainstem regions called the area postrema and the nucleus tractus solitarius, directly triggering the vomiting reflex.⁶

This discovery led to one of the few clinical success stories for drugs that block substance P’s receptor. Aprepitant, an NK1 receptor antagonist, is now a standard component of anti-nausea regimens given alongside chemotherapy. It specifically targets that delayed nausea that older anti-serotonin drugs could not fully prevent.⁷ The fact that blocking NK1 receptors reliably prevents vomiting but does not reliably prevent pain (more on that later) is one of the genuinely puzzling findings in substance P research.

Stress, Anxiety, and Mood

Substance P does not stay in its lane as a pain-and-nausea molecule. It is deeply embedded in the brain’s emotional circuitry, particularly in the amygdala, a region central to fear and anxiety. When animals are exposed to emotional stress, substance P floods into specific parts of the amygdala. Immobilization stress, for instance, caused a sustained 150% increase in substance P release in the medial nucleus of the amygdala in rats, while milder stress produced a smaller, transient rise of about 40%.⁸

The relationship between stress severity and substance P release appears to be graded: harsher stressors produce more substance P in limbic brain structures.⁹ Injecting an NK1 receptor blocker directly into the medial amygdala prevented stress-induced anxiety behavior in rats, while the same drug had no effect in unstressed animals. That detail matters because it suggests substance P is not maintaining baseline anxiety levels but rather amplifying the emotional response when something goes wrong.⁸

Early clinical trials of NK1 antagonists for depression showed promising results, and the link between substance P, chronic pain, and mood disorders remains an active area of interest. Given that elevated substance P levels are associated with major depressive disorder, anxiety disorders, and PTSD, the peptide sits at a neurochemical crossroads where pain and emotion overlap.⁴

The Gut-Brain Axis

The digestive tract contains an enormous number of nerve cells, sometimes called the “second brain,” and substance P is one of their key signaling molecules. It acts as both a neurotransmitter and a neuromodulator in the gut, helping regulate motility (the muscular contractions that push food along) and influencing the local immune environment. Under normal conditions this keeps digestion running smoothly, but when the system becomes dysregulated, substance P’s pro-inflammatory effects can worsen intestinal inflammation.¹⁰

In conditions like ulcerative colitis and Crohn’s disease, substance P levels in the gut wall tend to be abnormally high. The peptide promotes the release of inflammatory molecules from immune cells in the intestinal lining, worsening the cycle of damage and repair that characterizes inflammatory bowel disease. This connection has prompted research into whether blocking substance P’s receptor in the gut could ease symptoms, though no approved therapy has yet come from that line of work.

Itch and the Skin

Substance P has long been linked to itch, but the mechanism turned out to be more surprising than researchers expected. The conventional thinking was that substance P triggered itch by activating its usual NK1 receptor on sensory neurons and mast cells. However, experiments showed that substance P-induced scratching behavior in mice depended not on NK1 receptors but on a different family of receptors called Mas-related G protein-coupled receptors (Mrgprs) on sensory neurons.¹¹

This matters practically because it means that drugs designed to block NK1 receptors may not be the right tools for treating itch, even though they work for nausea and show promise for mood disorders. The itch pathway appears to run through a separate receptor system entirely, which could explain why some patients with chronic itch conditions do not respond well to NK1-targeted therapies.

Effects in the Lungs

Substance P is present in sensory nerves that line the airways, and when released there it causes bronchoconstriction, the tightening of the smooth muscle around the airways that makes breathing harder. Inhaled substance P caused a mean drop in airway conductance of nearly 50% in study participants, affecting both normal and asthmatic subjects.¹²

In animal models, substance P also promotes lung inflammation by activating mast cells in airway tissue, leading to the release of cytokines associated with the kind of immune response seen in asthma. Mice given substance P developed peribronchial inflammation, fibrosis, and elevated levels of allergy-associated signaling molecules.¹³ This dual action of constricting airways and promoting allergic-type inflammation places substance P squarely in the biology of asthma and chronic cough, though translating those findings into effective treatments has been slow.

Wound Healing and Tissue Repair

Not everything substance P does is harmful. The peptide plays a genuinely constructive role in wound healing. It stimulates the proliferation of fibroblasts (the cells that lay down structural tissue), promotes the growth of new blood vessels, and boosts the production of growth factors needed to rebuild damaged tissue.¹⁴

In diabetic rats, which are notorious for slow wound healing, topical application of substance P significantly accelerated wound closure. Treated wounds showed better formation of new tissue, denser networks of new blood vessels, earlier formation of a new skin layer, and greater numbers of regenerating nerve fibers compared to untreated wounds.¹⁵ Similar benefits have been observed in tendon healing, where injections of substance P led to faster collagen organization, an important factor in restoring a tendon’s strength.¹⁶ Alongside insulin-like growth factor-1, substance P and its breakdown products also promote healing of the corneal surface, a finding that has attracted interest for treating eye injuries.¹⁴

This regenerative side of substance P highlights a recurring theme: the same inflammatory and growth-promoting signals that cause trouble in chronic disease are exactly what the body needs in the short term after an injury.

Brain Injury and Edema

After a traumatic brain injury or stroke, substance P is released rapidly as part of a neurogenic inflammatory response in the central nervous system. That release makes the blood-brain barrier, normally a tightly controlled gatekeeper, become permeable. Fluid leaks from the blood into brain tissue, causing vasogenic edema, the dangerous swelling that accounts for much of the secondary damage after head injuries.¹⁷

The magnitude of substance P released after brain injury correlates with both the severity and the frequency of the insult.¹⁸ In animal studies, blocking substance P activity, either by preventing its release or by administering NK1 receptor antagonists, consistently produced large decreases in brain edema and clear improvements in functional recovery.¹⁹ These results have generated considerable interest in whether NK1 antagonists like aprepitant, already approved for nausea, could be repurposed to reduce brain swelling after trauma. Clinical trials in humans are still limited, but the preclinical data is unusually consistent.

Heart and Blood Vessels

Substance P influences heart rate, blood pressure, and blood vessel dilation, though its role in the cardiovascular system is less straightforward than in pain or nausea. It generally acts as a vasodilator, widening blood vessels and lowering blood pressure. It is also involved in how the heart responds to ischemia, the temporary loss of blood supply during events like a heart attack.²⁰

Intriguingly, substance P appears to play a dual role in heart disease depending on the timing and the type of injury. Short-term, in the immediate aftermath of a temporary blockage and restoration of blood flow, substance P seems protective. Long-term, in non-ischemic heart failure driven by chronic stress on the heart muscle, substance P signaling appears to contribute to harmful remodeling of the heart tissue.²¹ This kind of context-dependent behavior is common with substance P and is part of what makes developing drugs around it so tricky.

Bone Turnover and Joints

Sensory nerve fibers carrying substance P extend into bone and joint tissue, and the peptide directly influences the cells responsible for bone remodeling. NK1 receptors sit on both osteoblasts (the cells that build bone) and osteoclasts (the cells that break it down), and substance P stimulates the activity of both.²²

In joints affected by arthritis, substance P released from local nerves ramps up the production of a signaling molecule called RANKL in the synovial lining. RANKL drives osteoclast formation, accelerating bone erosion around inflamed joints.²³ This gives substance P a direct role in the joint destruction seen in rheumatoid arthritis and other inflammatory joint diseases, beyond just causing pain in those joints.

Substance P and Tumor Growth

A growing body of evidence connects substance P to cancer biology. The NK1 receptor is expressed by many types of tumor cells, and when substance P activates it, the result is cell proliferation, migration, and the formation of new blood vessels that feed tumor growth.²⁴ In laboratory experiments on esophageal cancer cells, substance P treatment promoted cell migration and boosted the expression of proteins involved in tissue invasion and blood vessel formation. Aprepitant, the NK1 antagonist already used for chemotherapy-induced nausea, blocked these effects.²⁵

When NK1 receptor antagonists are applied to tumor cells in the lab, they tend to trigger apoptosis, the programmed cell death that healthy cells undergo when damaged but cancer cells typically evade.²⁴ These findings are still largely preclinical, but the fact that aprepitant is already widely used and well-tolerated makes it a candidate for repurposing studies. Whether blocking NK1 receptors in a living patient translates to meaningful anti-tumor effects remains an open question.

Crosstalk with the Opioid System

The relationship between substance P and the body’s own painkilling opioid system is one of the more complicated chapters in pain biology. The two systems operate side by side in the spinal cord, often on the same neurons, and they influence each other in ways that matter for how well painkillers work.

At low spinal concentrations, substance P can actually reinforce the effect of morphine, seemingly by triggering the release of the body’s own endogenous opioid molecules in the local spinal cord environment. The dose-response curve for this effect follows an inverted-U shape: a little substance P boosts opioid pain relief, while a lot produces the more familiar pain-promoting effects.²⁶

Substance P also physically reprograms how opioid receptors behave inside nerve cells. When substance P activates its NK1 receptor, it triggers a chain of events that increases the recycling of mu-opioid receptors back to the cell surface, effectively resensitizing the cell to opioids. This cross-regulation was selective: it enhanced the pain-relieving effects of fentanyl in mice but not of morphine, suggesting the interaction depends on which opioid is involved.²⁷

Unfortunately, in chronic nerve injury the relationship breaks down. In animal models of neuropathic pain, the ability of opioid receptor activation to suppress substance P release was completely lost, even at very high opioid concentrations.²⁸ This loss of the opioid brake on substance P could help explain why neuropathic pain responds so poorly to opioid painkillers.

Why NK1 Antagonists Work for Nausea but Fail for Pain

Given how central substance P is to pain signaling in animals, it seemed almost inevitable that drugs blocking its receptor would be powerful painkillers. They were not. Clinical trials of NK1 receptor antagonists for a wide range of pain conditions, including postoperative pain, neuropathic pain, and migraine, consistently failed to show meaningful benefit.²⁹ The same class of drugs that reliably prevents chemotherapy-induced vomiting and showed early promise for depression had no detectable effect on human pain.³⁰

The reasons are still debated. One explanation is that pain in humans involves so many redundant signaling pathways that blocking just one, even an important one, is not enough. Another is that the relationship between substance P and pain in rodents, where much of the foundational research was done, may not perfectly mirror the human system. There is also the itch-receptor finding to consider: if substance P can activate entirely different receptor families depending on the tissue, then blocking NK1 receptors alone may miss substantial portions of its activity. Whatever the explanation, the disconnect between dramatic animal results and flat clinical trials remains one of the more humbling episodes in pain drug development. It also underscores that substance P’s biology is layered and context-dependent in ways that resist simple pharmacological fixes.

Receptor Complexity and Metabolite Signaling

Part of what makes substance P so difficult to target cleanly is that the story does not end once the peptide binds its receptor. After release, substance P is rapidly broken down by enzymes in the surrounding tissue, and some of those breakdown fragments are not inert. Certain fragments from the tail end of the molecule can still activate the NK1 receptor, though they produce a somewhat different intracellular response than the full-length peptide. Full substance P triggers both calcium release and a rise in a secondary messenger called cyclic AMP inside cells, while some of its metabolites shift the balance, still raising calcium but producing less cyclic AMP signaling.³¹ These subtleties suggest that the body may use substance P metabolism as a fine-tuning dial, adjusting the downstream effects of NK1 receptor activation depending on how quickly and in what way the peptide is processed. For drug developers, it means that simply blocking the receptor with a single antagonist may not capture the full complexity of what substance P does in any given tissue.